ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
Completed · Phase 1
Conditions studied: Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: ABT-888 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about the ways a patient's body handles the drug. PURPOSE: This early phase I trial is studying the side effects and best dose of ABT-888 in patients with refractory solid tumors or hematologic cancer.
Key facts
- Study ID
- NCT00387608
- Run by
- National Institutes of Health Clinical Center (CC)
- People needed
- 23
- Starts
- 2006-06-01
- Expected to finish
- 2009-04-01
- Last updated by the study team
- 2012-03-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.